GlassScriptPhysician profile
Kelsey M Schmidt
NPI 1366833709
$3,687.02
in general payments reported to CMS, 2019-2025
22 companies · $1,910 in 2025
The $1,910 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $176 · 2022: $109 · 2023: $201 · 2024: $1,292 · 2025: $1,910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,079 · Education: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,078.66 |
| Education | $323.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $637.50 | 2024-2025 | |
| Janssen Biotech, INC. | $514.02 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $347.84 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $316.96 | 2024-2025 | |
| Amgen INC. | $292.45 | 2021-2023 | Prolia, Evenity |
| Leo Pharma INC. | $221.19 | 2024-2025 | Adbry, Anzupgo |
| Radius Health, INC. | $192.89 | 2021-2023 | Tymlos |
| Springworks Therapeutics, INC. | $179.79 | 2025 | Gomekli |
| Regeneron Healthcare Solutions, INC. | $163.53 | 2024-2025 | Dupixent, Libtayo |
| Incyte Corporation | $135.31 | 2024 | Opzelura |
| Ucb, INC. | $113.69 | 2025 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $96.99 | 2025 | |
| Novartis Pharmaceuticals Corporation | $94.83 | 2025 | |
| Genzyme Corporation | $89.84 | 2024-2025 | |
| Organon LLC | $79.35 | 2025 | Vtama |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $39.15 | 2025 | Nemluvio |
| Reprise Biomedical, INC. | $38.14 | 2025 | Miro 3d |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.05 | 2024-2025 | Spevigo |
| Biowound Solutions, INC. | $30.00 | 2025 | Bio-Connekt |
| Organogenesis INC. | $29.72 | 2025 | Affinity |
| Biofrontera INC. | $21.75 | 2024 | Ameluz, Rhodoled Xl, Xepi |
| E.R. Squibb & Sons, L.L.C. | $20.03 | 2024 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.